Revenue Update on AMAG Pharmaceuticals(NASDAQ:AMAG)

AMAG Pharmaceuticals(NASDAQ:AMAG) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $132.47M. Analysts estimated a revenue of $128.70M. Earnings per share were $1.45. Analysts had estimated an EPS of $1.20.

AMAG Pharmaceuticals (AMAG) shares turned negative on Wednesdays trading session with the shares closing down -0.87 points or -3.39% at a volume of 6,19,854. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $25.72. The peak price level was also seen at $25.72 while the days lowest was $24.6. Finally the shares closed at $24.81. The 52-week high of the shares is $67.145 while the 52-week low is $17.92. According to the latest information available, the market cap of the company is $847 M.

Several Insider Transactions has been reported to the SEC. On Nov 10, 2015, John A. Fallon (director) purchased 3,230 shares at $31.20 per share price.Also, On Oct 2, 2015, William K Heiden (CEO) sold 2,000 shares at $39.69 per share price.On Aug 7, 2015, Frank E Thomas (President & COO) sold 15,000 shares at $66.85 per share price, according to the Form-4 filing with the securities and exchange commission.

AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AMAG Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on AMAG Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.